Candidate Urine Peptide Biomarkers for IgA Nephropathy: Where Are We Now?

Abstract EN

Early detection, prognosis, and management of IgA nephropathy (IgAN) remain a challenge.

Histological examination of renal tissue still comprises the only way to confirm an IgAN diagnosis.

It is of great importance to establish noninvasive diagnostic, prognostic, and predictive biomarkers that would improve the clinical care and outcome of patients suffering from IgAN.

This review summarises the findings from previous mass spectrometry- (MS-) based studies dedicated to the discovery of urinary peptide profiles specific to IgAN.

There is a substantial number of urinary peptides that have been discovered to date, which show promise as biomarkers of IgAN; however, all of them require further, rigorous validation in well-planned studies, involving a large number of subjects who represent diverse and numerous populations.